Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

clinical trial

Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT03882034

P6099clinical trial phasephase III clinical trialQ42824827
P17countryUnited States of AmericaQ30
P582end time2022-01-01
P4135maximum age18
P1050medical conditionacromegalyQ189580
P2899minimum age2
P1132number of participants60
P859sponsorEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentQ5409765
P580start time2019-03-27
P8363study typeinterventional studyQ78089383
P1476titleAn Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

Search more.